Gain detailed insights into the trading activity of Congress members for Xylem on our government trades page. Stay updated on how elected officials are investing in XYL.

Xylem - Government Trades

Xylem

Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $7.4 billion in revenue in 2023.

Earnings

News

Dividends

Markets

Analyst Ratings

Trading Ideas

Xylem Inc. (NYSE: XYL) is well-poised for growth in the coming quarters, courtesy of its businesses and accretive acquisitions. The company&#39;s efforts to reward its shareholders add to its appeal.

Here&#39;s Why You Should Retain Xylem Stock in Your Portfolio for Now

Large Cap

Sector ETFs

Asset Sales

ETFs

PowerShares Exchange Traded Fund Water Resource Portfolio

VLTO

If you&#39;re interested in broad exposure to the Industrials - Water segment of the equity market, look no further than the Invesco S&amp;P Global Water Index ETF (ARCA:CGW), a passively managed exchange traded fund launched on 05/14/2007.

Should You Invest in the Invesco S&amp;P Global Water Index ETF?

Equities

Guidance

Movers

AQWA

Xylem reported strong Q2 results, with revenue growth of 26%, adjusted EPS of $1.09, and raised its full-year guidance. 

Xylem&#39;s Water Wisdom Pays Off: Q2 Beats Estimates, Outlook Upgraded

Launched on 05/14/2007, the Invesco S&amp;P Global Water Index ETF (ARCA:CGW) is a passively managed exchange traded fund designed to provide a broad exposure to the Industrials - Water segment of the equity market.

Stocks Photo by Jirapong Manustrong on Shutterstock

Price Target

Xylem Analysts Cut Their Forecasts After Upbeat Earnings

Coinbase Photo by Useacoin on Shutterstock

AAPL

BKNG

COIN

CYRX

TXRH

Coinbase Global To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Friday

Short Ideas

Small Cap

Insider Trades

Pre-Market Outlook

DXCM

QNST

The Nasdaq 100 closed lower by around 0.4% on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Xylem, DexCom And 2 Other Stocks Insiders Are Selling

General

Xylem shines in Q4 FY23, boasting 41% revenue growth to $2.12 billion, surpassing market expectations. Orders and backlog surge, indicating robust demand and promising future prospects.
With impressive financial results and a confident outlook, Xylem  positions itself as a leader in the industry, projecting adjusted EPS of $4.00-$4.20 for FY24.

Why Water Technology Company Xylem Shares Are Seeing Blue Skies Today

Penny Stocks

CRWD

GDDY

KEYS

MYSZ

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

CrowdStrike To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Tuesday

Xylem Inc. (NYSE: XYL) reported third-quarter FY23 revenue growth of 50.4% Y/Y to $2.08 billion (+10% organically), 

Water Technology Company Xylem Records Solid Q3 Amid Intensifying Water Challenges; Revenue Soars 50.4%

Xylem Inc

XY Labs Inc

Global X Funds Global X S&P 500 Covered Call ETF

Global X Funds Global X S&P 500 ESG Covered Call ETF

Global X S&P 500 Covered Call & Growth ETF

Xylo Technologies Ltd. - American Depositary Shares

Xylo Technologies Ltd

Sweet Natural Trading Co Ltd

Analysts' ratings for Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $151.0, a high estimate of $166.00, and a low estimate of $125.00. Highlighting a 3.58% decrease, the current average has fallen from the previous average price target of $156.60. 
<img src="https://www.benzinga.com/files/images/story/2024/1734008428_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Xylem among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$166.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$148.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Joseph Giordano</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$125.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$162.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$154.00</td>
<td>$175.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Xylem. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Xylem compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Xylem's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Xylem's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/XYL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Xylem analyst ratings.</a>
<h2>About Xylem</h2>
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $7.4 billion in revenue in 2023.
<h3>Xylem: A Financial Overview</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Xylem's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.35% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 10.31%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Xylem's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.07%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Xylem's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.36%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.2.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Critical Insights From Xylem Analyst Ratings: What You Need To Know

Wolfe Research analyst Brad Hewitt downgrades Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) from Outperform to Peer Perform.

Downgrades

Wolfe Research Downgrades Xylem to Peer Perform

Stifel analyst Nathan Jones maintains Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) with a Buy and lowers the price target from $172 to $166.

Stifel Maintains Buy on Xylem, Lowers Price Target to $166

Companies will further integrate solutions that help utilities accelerate digitalization and tackle critical challenges such as water scarcity and aging infrastructure
Global water solutions company Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) today announced that it has acquired a majority stake in Idrica, a leader in water data management and analytics, to empower water utilities with intelligent solutions for their most critical challenges

VRAX

Virax Biolabs Partners With Tebubio To Broaden Access To ImmuneSelect in the European Union, Norway, And Switzerland

Companies will further integrate solutions that help utilities accelerate digitalization and tackle critical challenges such as water scarcity and aging infrastructure.
 &nbsp;

Xylem Acquires Majority Stake In Idrica; No Terms Disclosed

Citigroup analyst Andrew Kaplowitz upgrades Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) from Neutral to Buy and raises the price target from $135 to $148.

Upgrades

Citigroup Upgrades Xylem to Buy, Raises Price Target to $148

TD Cowen analyst Joseph Giordano maintains Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) with a Hold and lowers the price target from $138 to $125.

TD Cowen Maintains Hold on Xylem, Lowers Price Target to $125

RBC Capital analyst Deane Dray maintains Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) with a Outperform and lowers the price target from $163 to $162.

RBC Capital Maintains Outperform on Xylem, Lowers Price Target to $162

Baird analyst Michael Halloran maintains Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) with a Outperform and lowers the price target from $175 to $154.

Baird Maintains Outperform on Xylem, Lowers Price Target to $154

WIIM

Xylem shares are trading lower after the company reported worse-than-expected Q3 sales results and issued FY24 guidance below estimates.

Outlook
Xylem expects full-year 2024 revenue of $8.5 billion, up approximately 15 percent on a reported basis and up approximately 5 percent on an organic basis.
Full-year 2024 adjusted EBITDA margin is expected to be approximately 20.5 percent. This results in adjusted earnings per share of $4.22 to $4.24 from the previous range of $4.18 to $4.28. Full-year free cash flow conversion to net income is expected to be at least 120 percent.

Xylem Narrows 2024 Outlook: Now Expects Revenue Of $8.5B (Prior $8.55B) Vs. $8.528B Est., And Adj. EPS Of $4.22-4.24 (Prior $4.18-$4.28) Vs. $4.26 Est.

Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) reported quarterly earnings of $1.11 per share which met the analyst consensus estimate. This is a 12.12 percent increase over earnings of $0.99 per share from the same period last year. The company reported quarterly sales of $2.104 billion which missed the analyst consensus estimate of $2.175 billion by 3.26 percent. This is a 1.35 percent increase over sales of $2.076 billion the same period last year.

Earnings Misses

Xylem Q3 2024 Adj. EPS $1.11, Inline, Sales $2.104B Miss $2.175B Estimate

In the current session, the stock is trading at $133.65, after a 0.13% spike. Over the past month, Xylem Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) stock increased by 2.95%, and in the past year, by 45.35%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1728323108_0.png" alt="Past Year Chart" />

<h3>Xylem P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 28.81 in the Machinery industry, Xylem Inc. has a higher P/E ratio of 41.19. Shareholders might be inclined to think that Xylem Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1728323108_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

A Look Into Xylem Inc's Price Over Earnings

Xylem Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xyl#NYSE">XYL</a>) is well-poised for growth in the coming quarters, courtesy of its businesses and accretive acquisitions. The company&#39;s efforts to reward its shareholders add to its appeal.
Headquartered in Rye Brook, NY, Xylem is one of the leading providers of water solutions worldwide. It is involved in the full water-process cycle, including the collection, distribution and return of water to the environment. XYL has a significant presence in the United States, the Asia Pacific, Europe and various other nations. Over the past year, this Zacks Rank #3 (Hold) company has gained 40.4% compared with the industry&#39;s 26.8% growth.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/23/78263.jpg?v=976502451" />
Image Source: Zacks Investment Research
Let&#39;s discuss the factors that might influence investors to retain this stock in their portfolio for the time being.
Business Strength: Xylem is seeing growth across most of its businesses. The Measurement &amp; Control Solutions (&quot;M&amp;CS&quot;) segment is benefiting from robust demand for advanced technology solutions like smart metering and other applications, primarily in the United States. The segment&#39;s organic sales were up 26% year over year, driven by smart metering demand and execution.
Growth in the transport application business, driven by a strong pipeline of capital projects in Western Europe and increased infrastructure projects in the United States, is boosting the Water Infrastructure segment&#39;s performance. Strong momentum in the treatment applications business, supported by increasing capital projects in emerging markets, also bodes well. The segment&#39;s organic sales increased 7% year over year in the second quarter, buoyed by price realization and growth across all regions and applications.
Strength in dewatering business across major markets (particularly in the United States and emerging regions), driven by increased sales volume and favorable pricing, is a key catalyst to the Water Solutions and Services segment&#39;s growth. The segment&#39;s organic sales grew 12% year over year in the second quarter, supported by higher capital project revenues and gains in integrated solutions and services in the United States.
Expansion Efforts: The company solidifies its product portfolio and leverages business opportunities through asset additions. Acquisitions contributed $265 million to Xylem&#39;s total revenues in the second quarter. The company acquired mission-critical water treatment solutions and services provider Evoqua in May 2023.
Evoqua&#39;s advanced water and wastewater treatment capabilities and position in key industrial markets complement Xylem&#39;s portfolio of solutions across the water cycle. The acquisition boosted its position in water technologies, solutions and services. The transaction is expected to deliver run-rate cost synergies of $140 million within three years upon closing. It is also expected to strengthen the company&#39;s balance sheet.
Rewards to Shareholders: Xylem&#39;s commitment to rewarding shareholders through dividends and share buybacks is encouraging. In the first six months of 2024, it paid dividends of $175 million, up 25.9% year over year. The company also bought back shares worth $18 million in the same period. In February 2024, it hiked its dividend by 9%. Also, in 2023, Xylem paid out dividends worth $299 million and bought back shares worth $25 million.
<h2>Downsides of Xylem</h2>
Segmental Weakness: Xylem has been experiencing weakness in the Applied Water segment owing to the slowdown in the broader economy. In July 2024, the Institute for Supply Management&#39;s manufacturing index registered 48.5%, indicating a contraction in U.S. manufacturing activity for the third consecutive month. The impact of this slowdown is reflected in the decrease in demand for industrial and building solutions applications, including pumps, valves, heat exchangers, controls and dispensing equipment.
Amid these challenges, the segment&#39;s second-quarter revenues declined 5% on a year-over-year basis in the second quarter. A reduced number of project wins is likely to impact its performance in the near term.
Rising Costs: Xylem has been grappling with the adverse impacts of cost inflation. In the second quarter, its cost of revenues increased 26.1% year over year due to high raw material, labor, freight and overhead costs. Selling, general and administrative expenses rose 8.7% due to additional operational expenditure from the acquisition of Evoqua. Escalating costs pose a threat to the bottom line.
<h2>Stocks to Consider</h2>
Some better-ranked companies from the same space are discussed below.
Flowserve Corporation&nbsp;currently carries a Zacks Rank #2 (Buy).
FLS delivered a trailing four-quarter average earnings surprise of 18.2%. In the past 60 days, the Zacks Consensus Estimate for Flowserve&#39;s 2024 earnings has increased 3.8%.
Crane Company&nbsp;presently carries a Zacks Rank of 2. The company delivered a trailing four-quarter average earnings surprise of 11.2%.
In the past 60 days, the Zacks Consensus Estimate for CR&#39;s 2024 earnings has increased 2%.
Parker-Hannifin Corporation&nbsp;currently carries a Zacks Rank of 2. PH delivered a trailing four-quarter average earnings surprise of 2.6%.
In the past 60 days, the consensus estimate for Parker-Hannifin&#39;s fiscal 2025 earnings has increased 1.3%.
<a href="https://www.zacks.com/stock/news/2337929/here-s-why-you-should-retain-xylem-stock-in-your-portfolio-for-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2337929">To read this article on Zacks.com click here.</a>

Here's Why You Should Retain Xylem Stock in Your Portfolio for Now

If you&#39;re interested in broad exposure to the Industrials - Water segment of the equity market, look no further than the Invesco S&amp;P Global Water Index ETF (ARCA:CGW), a passively managed exchange traded fund launched on 05/14/2007.
Retail and institutional investors increasingly turn to passively managed ETFs because they offer low costs, transparency, flexibility, and tax efficiency; these kind of funds are also excellent vehicles for long term investors.
Sector ETFs also provide investors access to a broad group of companies in particular sectors that offer low risk and diversified exposure. Industrials - Water is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 13, placing it in bottom 19%.
<h2>Index Details</h2>
The fund is sponsored by Invesco. It has amassed assets over $971.84 million, making it one of the average sized ETFs attempting to match the performance of the Industrials - Water segment of the equity market. CGW seeks to match the performance of the S&amp;P GLOBAL WATER INDEX before fees and expenses.
The S&amp;P Global Water Index comprises of developed market securities including water utilities, infrastructure, equipment, instruments and materials.
<h2>Costs</h2>
Cost is an important factor in selecting the right ETF, and cheaper funds can significantly outperform their more expensive counterparts if all other fundamentals are the same.
Annual operating expenses for this ETF are 0.56%, making it on par with most peer products in the space.
It has a 12-month trailing dividend yield of 1.42%.
<h2>Sector Exposure and Top Holdings</h2>
Even though ETFs offer diversified exposure that minimizes single stock risk, investors should also look at the actual holdings inside the fund. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis.
Looking at individual holdings, American Water Works Co Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/awk#NYSE">AWK</a>) accounts for about 8.63% of total assets, followed by Xylem Inc/ny (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xyl#NYSE">XYL</a>) and Veralto Corp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vlto#NYSE">VLTO</a>).
The top 10 holdings account for about 52.72% of total assets under management.
<h2>Performance and Risk</h2>
The ETF has added roughly 8.91% and it&#39;s up approximately 19.45% so far this year and in the past one year (as of 09/09/2024), respectively. CGW has traded between $44.46 and $59.88 during this last 52-week period.
The ETF has a beta of 0.99 and standard deviation of 18.38% for the trailing three-year period, making it a low risk choice in the space. With about 74 holdings, it effectively diversifies company-specific risk.
<h2>Alternatives</h2>
Invesco S&amp;P Global Water Index ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, CGW is a sufficient option for those seeking exposure to the Industrials ETFs area of the market. Investors might also want to consider some other ETF options in the space.
First Trust Water ETF (ARCA:FIW) tracks ISE Clean Edge Water Index and the Invesco Water Resources ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pho#NASDAQ">PHO</a>) tracks NASDAQ OMX US Water Index. First Trust Water ETF has $1.75 billion in assets, Invesco Water Resources ETF has $2.15 billion. FIW has an expense ratio of 0.53% and PHO charges 0.60%.
<a href="https://www.zacks.com/stock/news/2333158/should-you-invest-in-the-invesco-s-p-global-water-index-etf-cgw?cid=CS-BENZ-FT-sector_etf-2333158">To read this article on Zacks.com click here.</a>

Should You Invest in the Invesco S&P Global Water Index ETF?

Xylem shares are trading lower after TD Cowen downgraded the stock from Buy to Hold and announced a $138 price target.

7 analysts have expressed a variety of opinions on Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $159.43, a high estimate of $172.00, and a low estimate of $138.00. This current average has increased by 2.59% from the previous average price target of $155.40. 
<img src="https://www.benzinga.com/files/images/story/2024/1725372054_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Xylem by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Giordano</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Hold</td>
<td>$138.00</td>
<td>-</td>
</tr>
<tr>
<td>Damian Karas</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$172.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$163.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$170.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Joseph Giordano</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$138.00</td>
<td>$135.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Xylem. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Xylem compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Xylem's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Xylem's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/XYL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Xylem analyst ratings.</a>
<h2>Unveiling the Story Behind Xylem</h2>
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $7.4 billion in revenue in 2023.
<h3>Xylem's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Xylem displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 25.96%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 8.94%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Xylem's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.89%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Xylem's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.22%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Xylem's debt-to-equity ratio is below the industry average. With a ratio of 0.2, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 7 Analysts Discuss Xylem Stock

TD Cowen analyst Joseph Giordano downgrades Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) from Buy to Hold and announces $138 price target.

TD Cowen Downgrades Xylem to Hold, Announces $138 Price Target

UBS analyst Damian Karas initiates coverage on Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) with a Buy rating and announces Price Target of $165.

Initiation

UBS Initiates Coverage On Xylem with Buy Rating, Announces Price Target of $165

Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $157.18, a high estimate of $172.00, and a low estimate of $135.00. Witnessing a positive shift, the current average has risen by 6.07% from the previous average price target of $148.18.
<img src="https://www.benzinga.com/files/images/story/2024/1722452456_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Xylem is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$172.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$163.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$170.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Joseph Giordano</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$138.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Bryan Blair</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$152.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>John Eade</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$165.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$162.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Bryan Blair</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$147.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Brett Linzey</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$135.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$155.00</td>
<td>$151.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Xylem. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Xylem compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Xylem's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Xylem's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/XYL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Xylem analyst ratings.</a>
<h2>About Xylem</h2>
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $7.4 billion in revenue in 2023.
<h3>Financial Insights: Xylem</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3 months period, Xylem showcased positive performance, achieving a revenue growth rate of 40.4% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Xylem's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 7.53%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Xylem's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.5%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Xylem's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.96%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Xylem's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.23.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 11 Analysts Discuss Xylem Stock

Janus Henderson Global Sustainable Equity ADR Managed Account Q3 2024 Commentary

Janus Henderson Global Sustainable Equity Fund Q3 2024 Commentary

Stocks with best odds of risk-adjusted returns deserve attention: Goldman Sachs

Citi upgraded Xylem (XYL) to Buy from Neutral with a price target of $148, up from $135. The firm sees good growth potential over time and a relati...

Xylem upgraded to Buy from Neutral at Citi

Xylem takes majority stake in Idrica

Stifel lowered the firm's price target on Xylem (XYL) to $166 from $172 and keeps a Buy rating on the shares. Global industrial stocks having mater...

Xylem price target lowered to $166 from $172 at Stifel

Wolfe Research downgraded Xylem (XYL) to Peer Perform from Outperform. Published first on TheFly – the ultimate source for real-time, market-moving...

Government Trades

Xylem Inc

top performing XYL trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga